Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.1105 | 1 | 1 |
Onchocerca volvulus | 0.0879 | 0.7135 | 0.6929 | |
Loa Loa (eye worm) | hypothetical protein | 0.0368 | 0.0672 | 0.061 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.1105 | 1 | 1 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0368 | 0.0672 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.1065 | 0.9489 | 1 |
Onchocerca volvulus | 0.1105 | 1 | 1 | |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0368 | 0.0672 | 0.061 |
Loa Loa (eye worm) | hypothetical protein | 0.1105 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0368 | 0.0672 | 0.0672 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0368 | 0.0672 | 0.5 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0368 | 0.0672 | 0.5 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0368 | 0.0672 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.1065 | 0.9489 | 1 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0368 | 0.0672 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0368 | 0.0672 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1105 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | > 30 uM | Inhibitory activity against interleukin-8 receptor using [125I]-IL8 | ChEMBL. | No reference |
Ki (binding) | > 30 uM | Inhibitory activity against interleukin-8 receptor using [125I]-IL8 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.